Does antibody to hepatitis B surface antigen protect renal transplant patients from hepatitis B?

Reactivation of hepatitis B virus with mutated hepatitis B surface antigen in a liver transplant recipient receiving a graft from an antibody to hepatitis B surface antigen– and antibody to hepatitis B core antigen–positive donor

BACKGROUND Fresh-frozen plasma (FFP) may contain antibodies to hepatitis B surface antigen (HBsAg, anti-HBs). These anti-HBs may lead to a misinterpretation of the actual hepatitis B immune status. Furthermore, they may not only confer protection against hepatitis B virus (HBV), but may also favor the selection of HBsAg mutants. CASE REPORT We report a case of de novo HBV infection in a HBV-n...

can Isolated hepatitis B core antibody in HIV-infected patients response to hepatitis B vaccine help to elucidate the cause?

EXPRESSION OF HEPATITIS B SURFACE ANTIGEN IN SACCHAROMYCES CEREVISIAE

The genome of HB V virus of serotype ayw cloned in pBR322 and expression shuttle vector p YES2 were used for construction of the HBsAg chimeric genes and their expression in Saccharomyces cerevisiae. Two recombinant plasmids were constructed. One of them contained the coding sequences for the major polypeptide of surface antigen. Another construct carried the major polypeptide with the pre-S2 a...

Living-donor kidney transplant from hepatitis B surface antigen-positive donors to hepatitis B antibody-positive recipients without hepatitis B immunoglobulin prophylaxis in an endemic country.

OBJECTIVES Living-donor kidney transplant from donors who are chronically infected with hepatitis B virus can be considered as a possibility to compensate for insufficiency of organ transplants, particularly in a hepatitis B virus endemic country. In this study, the safety and efficacy were reviewed retrospectively in living-donor kidney transplant from donors who were chronically infected with...

Occult hepatitis B in renal transplant patients.

BACKGROUND Occult hepatitis B (HB) is characterized by the presence of HBV-DNA in patients who do not have HB surface antigen (HBsAg) detectable in sera, and is frequently described in patients with hepatitis C virus (HCV) infection. These viral liver diseases are common and may have a negative impact on the survival of renal transplant patients, especially if they are both present. In this stu...